{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:06:52Z","timestamp":1774969612050,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Natural Science Plan in Shaanxi Province of China","award":["No.2024SF-ZDCYL-02-08"],"award-info":[{"award-number":["No.2024SF-ZDCYL-02-08"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Fund of China","doi-asserted-by":"crossref","award":["No.82172798"],"award-info":[{"award-number":["No.82172798"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01869-8","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T05:01:26Z","timestamp":1761368486000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Axillary lymph node dissection offers no survival benefit in breast cancer patients with sentinel lymph node micrometastases after neoadjuvant therapy"],"prefix":"10.1007","volume":"25","author":[{"given":"Jianing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhe","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenglong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsui","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danni","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"issue":"13","key":"1869_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39(13):1485\u2013505. https:\/\/doi.org\/10.1200\/JCO.20.03399.","journal-title":"J Clin Oncol"},{"key":"1869_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5913","volume":"360","author":"JS Vaidya","year":"2018","unstructured":"Vaidya JS, Massarut S, Vaidya HJ, et al. Rethinking neoadjuvant chemotherapy for breast cancer. BMJ. 2018;360:j5913. https:\/\/doi.org\/10.1136\/bmj.j5913.","journal-title":"BMJ"},{"issue":"3","key":"1869_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1001\/jamaoncol.2017.4000","volume":"4","author":"AS Heerdt","year":"2018","unstructured":"Heerdt AS. Lymphatic mapping and sentinel lymph node biopsy for breast cancer. JAMA Oncol. 2018;4(3):431. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4000.","journal-title":"JAMA Oncol"},{"key":"1869_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.breast.2017.08.006","volume":"36","author":"E Esposito","year":"2017","unstructured":"Esposito E, Di Micco R, Gentilini OD. Sentinel node biopsy in early breast cancer. A review on recent and ongoing randomized trials. Breast. 2017;36:14\u20139. https:\/\/doi.org\/10.1016\/j.breast.2017.08.006.","journal-title":"Breast"},{"key":"1869_CR5","unstructured":"Network NCC. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 3.2024). Plymouth Meeting, PA: National Comprehensive Cancer Network; 2024."},{"issue":"2","key":"1869_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andre F, Bachelot T, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(2):159\u201382. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016.","journal-title":"Ann Oncol"},{"issue":"14","key":"1869_CR7","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1200\/JCO-25-00099","volume":"43","author":"KU Park","year":"2025","unstructured":"Park KU, Somerfield MR, Anne N, et al. Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2025;43(14):1720\u201341. https:\/\/doi.org\/10.1200\/JCO-25-00099.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1869_CR8","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1200\/JCO.2007.15.5630","volume":"26","author":"JA Olson Jr","year":"2008","unstructured":"Olson JA Jr, McCall LM, Beitsch P, et al. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J Clin Oncol. 2008;26(21):3530\u20135. https:\/\/doi.org\/10.1200\/JCO.2007.15.5630.","journal-title":"J Clin Oncol"},{"issue":"24","key":"1869_CR9","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1200\/JCO.2006.07.4062","volume":"25","author":"A Lucci","year":"2007","unstructured":"Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25(24):3657\u201363. https:\/\/doi.org\/10.1200\/JCO.2006.07.4062.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1869_CR10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/CEJ.0000000000000821","volume":"32","author":"R Di Micco","year":"2023","unstructured":"Di Micco R, Fontana SKR, Gentilini OD, Galimberti V. Micrometastases in the sentinel node after neoadjuvant therapy. Is axillary dissection still required? Eur J Cancer Prev. 2023;32(6):544\u20137. https:\/\/doi.org\/10.1097\/CEJ.0000000000000821.","journal-title":"Eur J Cancer Prev"},{"issue":"1","key":"1869_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35567","volume":"131","author":"DS Shin","year":"2025","unstructured":"Shin DS, Ryu JM, Lee SK, et al. Nonsentinel lymph node metastases in cases of micrometastasis detected by sentinel lymph node biopsy after neoadjuvant chemotherapy. Cancer. 2025;131(1):e35567. https:\/\/doi.org\/10.1002\/cncr.35567.","journal-title":"Cancer"},{"issue":"1","key":"1869_CR12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s12957-024-03547-7","volume":"22","author":"M Muslumanoglu","year":"2024","unstructured":"Muslumanoglu M, Mollavelioglu B, Cabioglu N, et al. Axillary lymph node dissection is not required for breast cancer patients with minimal axillary residual disease after neoadjuvant chemotherapy. World J Surg Oncol. 2024;22(1):286. https:\/\/doi.org\/10.1186\/s12957-024-03547-7.","journal-title":"World J Surg Oncol"},{"issue":"2","key":"1869_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139. https:\/\/doi.org\/10.3322\/caac.21388.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1869_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4132\/jptm.2015.11.23","volume":"50","author":"SK Apple","year":"2016","unstructured":"Apple SK. Sentinel lymph node in breast cancer: review article from a pathologist\u2019s point of view. J Pathol Transl Med. 2016;50(2):83\u201395. https:\/\/doi.org\/10.4132\/jptm.2015.11.23.","journal-title":"J Pathol Transl Med"},{"key":"1869_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejca.2016.08.003","volume":"67","author":"G Houvenaeghel","year":"2016","unstructured":"Houvenaeghel G, Boher JM, Reyal F, et al. Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sentinel nodes. Eur J Cancer. 2016;67:106\u201318. https:\/\/doi.org\/10.1016\/j.ejca.2016.08.003.","journal-title":"Eur J Cancer"},{"issue":"12","key":"1869_CR16","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1136\/jcp.55.12.932","volume":"55","author":"MA den Bakker","year":"2002","unstructured":"den Bakker MA, van Weeszenberg A, de Kanter AY, et al. Non-sentinel lymph node involvement in patients with breast cancer and sentinel node micrometastasis; too early to abandon axillary clearance. J Clin Pathol. 2002;55(12):932\u20135. https:\/\/doi.org\/10.1136\/jcp.55.12.932.","journal-title":"J Clin Pathol"},{"issue":"6","key":"1869_CR17","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.surge.2012.01.003","volume":"10","author":"DP Joyce","year":"2012","unstructured":"Joyce DP, Solon JG, Prichard RS, Power C, Hill AD. Is there a requirement for axillary lymph node dissection following identification of micro-metastasis or isolated tumour cells at sentinel node biopsy for breast cancer? Surgeon. 2012;10(6):326\u20139. https:\/\/doi.org\/10.1016\/j.surge.2012.01.003.","journal-title":"Surgeon"},{"issue":"10","key":"1869_CR18","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1002\/ijc.27499","volume":"131","author":"TF Tvedskov","year":"2012","unstructured":"Tvedskov TF, Jensen MB, Lisse IM, et al. High risk of non-sentinel node metastases in a group of breast cancer patients with micrometastases in the sentinel node. Int J Cancer. 2012;131(10):2367\u201375. https:\/\/doi.org\/10.1002\/ijc.27499.","journal-title":"Int J Cancer"},{"issue":"6","key":"1869_CR19","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569\u201375. https:\/\/doi.org\/10.1001\/jama.2011.90.","journal-title":"JAMA"},{"issue":"3","key":"1869_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/SLA.0b013e3181f08f32","volume":"252","author":"AE Giuliano","year":"2010","unstructured":"Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426\u201332. https:\/\/doi.org\/10.1097\/SLA.0b013e3181f08f32. (discussion 432-423).","journal-title":"Ann Surg"},{"issue":"10","key":"1869_CR21","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial. JAMA. 2017;318(10):918\u201326. https:\/\/doi.org\/10.1001\/jama.2017.11470.","journal-title":"JAMA"},{"issue":"10","key":"1869_CR22","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","volume":"19","author":"V Galimberti","year":"2018","unstructured":"Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23\u201301): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(10):1385\u201393. https:\/\/doi.org\/10.1016\/S1470-2045(18)30380-2.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1869_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","volume":"14","author":"V Galimberti","year":"2013","unstructured":"Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23\u201301): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297\u2013305. https:\/\/doi.org\/10.1016\/S1470-2045(13)70035-4.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1869_CR24","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/bjs\/znab141","volume":"108","author":"Y Andersson","year":"2021","unstructured":"Andersson Y, Bergkvist L, Frisell J, de Boniface J. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial. Br J Surg. 2021;108(9):1105\u201311. https:\/\/doi.org\/10.1093\/bjs\/znab141.","journal-title":"Br J Surg"},{"key":"1869_CR25","doi-asserted-by":"publisher","first-page":"1012646","DOI":"10.3389\/fonc.2022.1012646","volume":"12","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Pu S, Jiang S, et al. The prognostic significance of further axillary dissection for sentinel lymph node micrometastases in female breast cancer: a competing risk analysis using the SEER database. Front Oncol. 2022;12:1012646. https:\/\/doi.org\/10.3389\/fonc.2022.1012646.","journal-title":"Front Oncol"},{"issue":"2","key":"1869_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1023\/a:1023002322935","volume":"14","author":"PA Wingo","year":"2003","unstructured":"Wingo PA, Jamison PM, Hiatt RA, et al. Building the infrastructure for nationwide cancer surveillance and control\u2013a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control. 2003;14(2):175\u201393. https:\/\/doi.org\/10.1023\/a:1023002322935.","journal-title":"Cancer Causes Control"},{"key":"1869_CR27","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2147\/CMAR.S185212","volume":"11","author":"N Shao","year":"2019","unstructured":"Shao N, Xie C, Shi Y, et al. Comparison of the 7th and 8th edition of American Joint Committee on Cancer (AJCC) staging systems for breast cancer patients: a Surveillance, Epidemiology and End Results (SEER) analysis. Cancer Manag Res. 2019;11:1433\u201342. https:\/\/doi.org\/10.2147\/CMAR.S185212.","journal-title":"Cancer Manag Res"},{"issue":"3","key":"1869_CR28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.7150\/jca.28991","volume":"10","author":"W Sun","year":"2019","unstructured":"Sun W, Cheng M, Zhou H, Huang W, Qiu Z. Nomogram predicting cause-specific mortality in nonmetastatic male breast cancer: a competing risk analysis. J Cancer. 2019;10(3):583\u201393. https:\/\/doi.org\/10.7150\/jca.28991.","journal-title":"J Cancer"},{"issue":"1","key":"1869_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cmpb.2010.02.004","volume":"100","author":"T Filleron","year":"2010","unstructured":"Filleron T, Laplanche A, Boher JM, Kramar A. An R function to non-parametric and piecewise analysis of competing risks survival data. Comput Methods Programs Biomed. 2010;100(1):24\u201338. https:\/\/doi.org\/10.1016\/j.cmpb.2010.02.004.","journal-title":"Comput Methods Programs Biomed"},{"issue":"1","key":"1869_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","volume":"23","author":"C Yau","year":"2022","unstructured":"Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022;23(1):149\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(21)00589-1.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1869_CR31","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1186\/s12885-019-6311-z","volume":"19","author":"R Wang","year":"2019","unstructured":"Wang R, Zhu Y, Liu X, et al. The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer. 2019;19(1):1091. https:\/\/doi.org\/10.1186\/s12885-019-6311-z.","journal-title":"BMC Cancer"},{"issue":"4","key":"1869_CR32","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jamaoncol.2022.7705","volume":"9","author":"KF Hoskins","year":"2023","unstructured":"Hoskins KF, Calip GS, Huang HC, et al. Association of social determinants and tumor biology with racial disparity in survival from early-stage, hormone-dependent breast cancer. JAMA Oncol. 2023;9(4):536\u201345. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7705.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1869_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00428-021-03141-2","volume":"480","author":"C van Dooijeweert","year":"2022","unstructured":"van Dooijeweert C, van Diest PJ, Ellis IO. Grading of invasive breast carcinoma: the way forward. Virchows Arch. 2022;480(1):33\u201343. https:\/\/doi.org\/10.1007\/s00428-021-03141-2.","journal-title":"Virchows Arch"},{"key":"1869_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155732","volume":"265","author":"T Zombori","year":"2025","unstructured":"Zombori T, Ferenczi A, Sejben A, et al. The prognostic value of histological grade determined after neoadjuvant chemotherapy of breast cancer. Pathol Res Pract. 2025;265:155732. https:\/\/doi.org\/10.1016\/j.prp.2024.155732.","journal-title":"Pathol Res Pract"},{"issue":"173","key":"1869_CR35","first-page":"189","volume":"34","author":"C Gao","year":"2022","unstructured":"Gao C, Wang J, He P, Xiong X. Metastatic pattern of breast cancer by histologic grade: a SEER population-based study. Discov Med. 2022;34(173):189\u201397.","journal-title":"Discov Med"},{"issue":"1","key":"1869_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s43046-021-00096-y","volume":"33","author":"KS Shohdy","year":"2021","unstructured":"Shohdy KS, Almeldin DS, Fekry MA, et al. Pathological responses and survival outcomes in patients with locally advanced breast cancer after neoadjuvant chemotherapy: a single-institute experience. J Egypt Natl Canc Inst. 2021;33(1):39. https:\/\/doi.org\/10.1186\/s43046-021-00096-y.","journal-title":"J Egypt Natl Canc Inst"},{"key":"1869_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.585613","volume":"11","author":"Y Liu","year":"2021","unstructured":"Liu Y, He M, Zuo WJ, et al. Tumor size still impacts prognosis in breast cancer with extensive nodal involvement. Front Oncol. 2021;11:585613. https:\/\/doi.org\/10.3389\/fonc.2021.585613.","journal-title":"Front Oncol"},{"issue":"1","key":"1869_CR38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13000-023-01433-6","volume":"19","author":"H Dou","year":"2024","unstructured":"Dou H, Li F, Wang Y, et al. Estrogen receptor-negative\/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy. Diagn Pathol. 2024;19(1):5. https:\/\/doi.org\/10.1186\/s13000-023-01433-6.","journal-title":"Diagn Pathol"},{"key":"1869_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102387","volume":"56","author":"Z Lu","year":"2025","unstructured":"Lu Z, Wang T, Wang L, Ming J. Research progress on estrogen receptor-positive\/progesterone receptor-negative breast cancer. Transl Oncol. 2025;56:102387. https:\/\/doi.org\/10.1016\/j.tranon.2025.102387.","journal-title":"Transl Oncol"},{"issue":"1","key":"1869_CR40","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12957-024-03365-x","volume":"22","author":"DM Peng","year":"2024","unstructured":"Peng DM, Li J, Qiu JX, Zhao L. Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China. World J Surg Oncol. 2024;22(1):88. https:\/\/doi.org\/10.1186\/s12957-024-03365-x.","journal-title":"World J Surg Oncol"},{"issue":"9938","key":"1869_CR41","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8.","journal-title":"Lancet"},{"issue":"5","key":"1869_CR42","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.clbc.2024.04.006","volume":"24","author":"D Guan","year":"2024","unstructured":"Guan D, Shi Q, Zheng Y, Zheng C, Meng X. Real-world data on pathological response and survival outcomes after neoadjuvant chemotherapy in HER2-low breast cancer patients. Clin Breast Cancer. 2024;24(5):463\u201372. https:\/\/doi.org\/10.1016\/j.clbc.2024.04.006.","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"1869_CR43","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288\u2013300. https:\/\/doi.org\/10.1001\/jama.2018.19323.","journal-title":"JAMA"},{"issue":"6","key":"1869_CR44","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","volume":"27","author":"N Howlader","year":"2018","unstructured":"Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27(6):619\u201326. https:\/\/doi.org\/10.1158\/1055-9965.EPI-17-0627.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"1869_CR45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/BD-210043","volume":"41","author":"S Salinas-Huertas","year":"2022","unstructured":"Salinas-Huertas S, Luzardo-Gonzalez A, Vazquez-Gallego S, et al. Risk factors for lymphedema after breast surgery: a prospective cohort study in the era of sentinel lymph node biopsy. Breast Dis. 2022;41(1):97\u2013108. https:\/\/doi.org\/10.3233\/BD-210043.","journal-title":"Breast Dis"},{"key":"1869_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103812","volume":"78","author":"Y Liang","year":"2024","unstructured":"Liang Y, Zhou Y, Houben R, et al. A systematic review and meta-analysis of risk factors influencing patient-reported arm symptoms post-breast cancer treatment: accounting for radiotherapy impact. Breast. 2024;78:103812. https:\/\/doi.org\/10.1016\/j.breast.2024.103812.","journal-title":"Breast"},{"issue":"4","key":"1869_CR47","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/SLA.0000000000005671","volume":"277","author":"NA Che Bakri","year":"2023","unstructured":"Che Bakri NA, Kwasnicki RM, Khan N, et al. Impact of axillary lymph node dissection and sentinel lymph node biopsy on upper limb morbidity in breast cancer patients: a systematic review and meta-analysis. Ann Surg. 2023;277(4):572\u201380. https:\/\/doi.org\/10.1097\/SLA.0000000000005671.","journal-title":"Ann Surg"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01869-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01869-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01869-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:52:14Z","timestamp":1764917534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01869-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1869"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01869-8","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The studies involving human participants were reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Xi\u2019an Jiaotong University. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"319"}}